United States — Food and Drug Administration & Revolution Medicines
6 shared events · Importance 3 · Last updated Aug 27, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States — Food and Drug Administration: The FDA granted expedited approval to daraxonrasib, marking a regulatory milestone and demonstrating its commitment to accelerating cancer treatments. The approval was issued 6.5 months ahead of schedule, reflecting the agency's priority review process.
Revolution Medicines: Revolution Medicines received FDA approval for its lead drug daraxonrasib (Rasonque), a first-in-class RAS inhibitor. The approval is expected to drive substantial revenue growth, with analysts projecting up to $11.5 billion in annual sales, and the company's stock has risen 166% this year.
Aug 26, 2026 · 92 articles
Tech
United States — Food and Drug Administration: Granted expedited approval of daraxonrasib more than six months ahead of its target date, reinforcing its accelerated-review posture for serious diseases.
Revolution Medicines: Secures first approval and commercial launch of daraxonrasib under the Rasonque brand at about $39,800 per month, validating its KRAS molecular glue platform and opening expansion into other cancers.
Aug 26, 2026 · 6 articles
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration is expediting the review of daraxonrasib and has allowed expanded access to the drug, indicating its critical role in bringing this new treatment to patients.
Revolution Medicines: Revolution Medicines developed daraxonrasib, the experimental drug that has shown significant promise in treating advanced pancreatic cancer, leading to increased attention and potential for market growth for the company.
May 29, 2026 · 74 articles
Regulatory
United States — Food and Drug Administration: The FDA is reviewing a rolling NDA for daraxonrasib under a priority voucher program, which could expedite U.S. approval.
Revolution Medicines: Revolution Medicines is the developer of daraxonrasib; the EMA phased review and FDA submission progress are key regulatory milestones that could lead to market approval and significant revenue.
Jul 07, 2026 · 7 articles
Tech
United States — Food and Drug Administration: The FDA granted Orphan Drug Designation for PRP in pancreatic cancer, which provides regulatory support and potential market exclusivity.
Revolution Medicines: Revolution Medicines' daraxonrasib is referenced as a comparator with strong Phase 3 results. The comparison highlights the competitive landscape but does not directly impact its operations.
Aug 27, 2026 · 6 articles
International
United States — Food and Drug Administration: The United States — Food and Drug Administration is the regulatory body that Revolution Medicines will seek approval from for its experimental pancreatic cancer drug, daraxonrasib.
Revolution Medicines: Revolution Medicines is the maker of daraxonrasib, an experimental pill showing promise for advanced pancreatic cancer, and plans to seek United States — Food and Drug Administration approval.
May 18, 2026 · 316 articles
100
United States — Food and Drug Administration approved Revolution MedicinesFDA Approves Daraxonrasib...
40
United States — Food and Drug Administration granted breakthrough designation Revolution MedicinesFDA Approves Daraxonrasib...
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and Revolution Medicines interact across events, view sentiment trends, and discover connected entities.
Open Dashboard